Artificial intelligence is rapidly transforming the pharmaceutical industry, dramatically reducing the time and cost required to develop new medicines before they ever reach human testing, according to a new survey.
A proprietary survey conducted by investment bank TD Cowen and reported by Axios found that AI-powered tools are cutting preclinical drug development costs and timelines by as much as 70%.